Phase 1 Trial for a New PSMA Radioligand 177Lu‑PSMA‑VG01

/in , , /by

177Lu‑PSMA‑VG01 is a next‑generation, small‑molecule PSMA‑targeting radiopharmaceutical designed to refine what 177Lu‑PSMA‑617 (Pluvicto) has already achieved. It uses a high‑affinity ligand to deliver the beta‑emitter lutetium‑177 directly to PSMA‑expressing tumor cells, aiming for greater tumor dosing with less exposure of healthy tissue. A new phase 1 trial is testing its dosimetry and side effects on […]

Read more

Darolutamide Versus Abiraterone-Based Triplets in mHSPC: Real-World Signals from the ARON-3 Study

/in /by

Using data from the international ARON-3 real-world study, investigators performed a retrospective head-to-head comparison of darolutamide- and abiraterone-based triplet therapy in patients with metastatic hormone-sensitive prostate cancer. The comparison included 247 patients treated with darolutamide plus docetaxel plus androgen deprivation therapy or abiraterone plus docetaxel plus androgen deprivation therapy across 37 institutions in 14 countries. […]

Read more

A New Clue for Prostate Cancer Survival

/in , /by

A recent study, published on Nature, looked at a question that matters just as much as prostate cancer risk: why do some tumors stay quiet while others become life-threatening after diagnosis? The researchers searched for genes whose activity might be linked to survival, not just to the chance of developing the disease. To do this, […]

Read more

Dual-Targeting PSMA And FRα Drug Conjugate Advances to U.S. Trial for Prostate Cancer

/in , , , /by

MVB-101 (aka CBP-1018) is a new clinical-stage drug conjugate for prostate cancer simultaneously targets PSMA and folate receptor alpha (FRα) to overcome tumor heterogeneity. The drug is a bivalent peptide-like drug conjugate roughly one-fiftieth the size of a traditional antibody drug conjugate, designed to diffuse more rapidly into solid tumors. It delivers monomethyl auristatin E […]

Read more

Phase 1 RIALTO Trial: Radiotherapy for Metastatic Prostate Cancer With Incomplete Hormone Response

/in , , /by

The RIALTO trial challenges decades of oncology dogma that treating the prostate becomes irrelevant once cancer spreads. For patients with de novo metastasized prostate cancer who show incomplete PSA-response (PSA >0.2 ng/ml after six months of combined ADT+ARPI), the prostate may function as a persistent tumor reservoir continuously seeding metastases. Local radiotherapy to the prostate […]

Read more

Decipher Genomic Classifier Identifies Patients Who Benefit from Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer

/in /by

A major advancement in metastatic hormone-sensitive prostate cancer has emerged from the ENZAMET trial: analysis using the Decipher genomic classifier shows that men with very high-risk tumor profiles benefit significantly from adding docetaxel to standard hormone therapy. Patients with a Decipher score above 0.85 who received the triplet regimen (ADT plus enzalutamide plus docetaxel) had […]

Read more

CRISPR Advances

/in /by

A single infusion of a CRISPR-based therapy has significantly reduced attacks in patients with hereditary angioedema (HAE) in what appears to be the first successful Phase III trial of an in vivo gene-editing treatment. The findings, presented at a major European congress and published in the New England Journal of Medicine, mark a turning point […]

Read more

Turning Prostate Cancer from Cold to Hot: How Tiny Silica Particles Kill Tumors and Wake Up the Immune System

/in , /by

For years, advanced prostate cancer has been the textbook example of an “immunologically cold” tumor: it doesn’t provoke a strong immune response, carries few mutations that help the immune system recognize cancer, and is packed with cells that actively suppress immunity. Because of this, immune checkpoint inhibitors have largely failed in this disease. Against this […]

Read more